Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling

Objectives We have previously described the antifibrotic role of the soluble guanylate cyclase (sGC). The mode of action, however, remained elusive. In the present study, we describe a novel link between sGC signalling and transforming growth factor β (TGFβ) signalling that mediates the antifibrotic effects of the sGC. Methods Human fibroblasts and murine sGC knockout fibroblasts were treated with the sGC stimulator BAY 41-2272 or the stable cyclic guanosine monophosphate (cGMP) analogue 8-Bromo-cGMP and stimulated with TGFβ. sGC knockout fibroblasts were isolated from sGCIfl/fl mice, and recombination was induced by Cre-adenovirus. In vivo, we studied the antifibrotic effects of BAY 41-2272 in mice overexpressing a constitutively active TGF-β1 receptor. Results sGC stimulation inhibited TGFβ-dependent fibroblast activation and collagen release. sGC knockout fibroblasts confirmed that the sGC is essential for the antifibrotic effects of BAY 41-2272. Furthermore, 8-Bromo-cGMP reduced TGFβ-dependent collagen release. While nuclear p-SMAD2 and 3 levels, SMAD reporter activity and transcription of classical TGFβ target genes remained unchanged, sGC stimulation blocked the phosphorylation of ERK. In vivo, sGC stimulation inhibited TGFβ-driven dermal fibrosis but did not change p-SMAD2 and 3 levels and TGFβ target gene expression, confirming that non-canonical TGFβ pathways mediate the antifibrotic sGC activity. Conclusions We elucidated the antifibrotic mode of action of the sGC that increases cGMP levels, blocks non-canonical TGFβ signalling and inhibits experimental fibrosis. Since sGC stimulators have shown excellent efficacy and tolerability in phase 3 clinical trials for pulmonary arterial hypertension, they may be further developed for the simultaneous treatment of fibrosis and vascular disease in systemic sclerosis.

[1]  G. Schett,et al.  Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. , 2015, Annals of the rheumatic diseases.

[2]  G. Schett,et al.  Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability , 2014, Annals of the rheumatic diseases.

[3]  G. Schett,et al.  Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis , 2014, Annals of the rheumatic diseases.

[4]  Chen Wang,et al.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.

[5]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[6]  J. Distler,et al.  Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. , 2013, Biochimica et biophysica acta.

[7]  J. Varga,et al.  Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis , 2013, Annals of the rheumatic diseases.

[8]  G. Schett,et al.  Activation of pregnane X receptor inhibits experimental dermal fibrosis , 2013, Annals of the rheumatic diseases.

[9]  J. Stasch,et al.  The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy , 2012, PloS one.

[10]  P. Berger,et al.  Therapeutic Targeting of Redox Signaling in Myofibroblast Differentiation and Age-Related Fibrotic Disease , 2012, Oxidative medicine and cellular longevity.

[11]  J. Kern,et al.  Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. , 2012, Endocrinology.

[12]  G. Schett,et al.  Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis , 2012, Annals of the rheumatic diseases.

[13]  Veronika Lang,et al.  Inhibition of sumoylation prevents experimental fibrosis , 2012, Annals of the rheumatic diseases.

[14]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[15]  O. Distler,et al.  Innovative antifibrotic therapies in systemic sclerosis , 2012, Current opinion in rheumatology.

[16]  Oliver Distler,et al.  Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. , 2012, Arthritis and rheumatism.

[17]  M. Taketo,et al.  β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis , 2012, Annals of the rheumatic diseases.

[18]  G. Schett,et al.  Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis , 2012, Annals of the rheumatic diseases.

[19]  Oliver Distler,et al.  Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis , 2012, Nature Communications.

[20]  O. V. Evgenov,et al.  Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats , 2011, PloS one.

[21]  N. Alenina,et al.  Platelet-derived serotonin links vascular disease and tissue fibrosis , 2011, The Journal of experimental medicine.

[22]  M. Yaniv,et al.  The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis , 2011, Annals of the rheumatic diseases.

[23]  G. Untergasser,et al.  Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. , 2010, Endocrinology.

[24]  R. Kalluri,et al.  Methylation determines fibroblast activation and fibrogenesis in the kidney , 2010, Nature Medicine.

[25]  J. Stasch,et al.  Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart , 2009, Hypertension Research.

[26]  B. Pasche,et al.  Transforming growth factor β as a therapeutic target in systemic sclerosis , 2009, Nature Reviews Rheumatology.

[27]  O. Distler,et al.  Imatinib as a novel therapeutic approach for fibrotic disorders. , 2008, Rheumatology.

[28]  J. Stasch,et al.  Nitric Oxide-independent Activation of Soluble Guanylate Cyclase by BAY 60-2770 in Experimental Liver Fibrosis , 2008, Arzneimittel-Forschung (Drug Research).

[29]  R. Gay,et al.  Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. , 2007, Arthritis and rheumatism.

[30]  A. Friebe,et al.  Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase , 2007, Proceedings of the National Academy of Sciences.

[31]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[32]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[33]  J. Pannu,et al.  Recent advances in fibroblast signaling and biology in scleroderma , 2004, Current opinion in rheumatology.

[34]  K. Mulhall,et al.  Basic and translational research , 2011 .

[35]  A. Friebe,et al.  Genetic mouse models of the NO receptor 'soluble' guanylyl cyclases. , 2009, Handbook of experimental pharmacology.

[36]  Mark R. Miller,et al.  NO and sGC-stimulating NO donors. , 2009, Handbook of experimental pharmacology.

[37]  H. Kawachi,et al.  Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. , 2006, American journal of physiology. Renal physiology.